



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. DO. 1450
Alexandria, Virginia 22313-1450
www.usdo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/766,122	01/27/2004	Torsten Hoffmann	21558	2112
151 7	590 09/02/2005		EXAMINER	
HOFFMANN-LA ROCHE INC.			HABTE, KAHSAY	
PATENT LAW DEPARTMENT 340 KINGSLAND STREET		ART UNIT	PAPER NUMBER	
NUTLEY, NJ	07110		1624	
			DATE MAILED: 09/02/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

4) . ,	Application No.	Applicant(s)				
	10/766,122	HOFFMANN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Kahsay Habte, Ph. D.	1624				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 22 Au	<u>igust 2005</u> .					
2a) This action is FINAL. 2b) ☑ This	<u> </u>					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1-30 is/are pending in the application.						
4a) Of the above claim(s) 16-27 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-15</u> is/are rejected.						
7) Claim(s) 28-30 is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on <u>27 January 2004</u> is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Reptacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:						
1.⊠ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)	43 D Janes Janes Commen	(PTO 412)				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da	nte				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5/6/2004.	5) Notice of Informal P 6) Other:	atent Application (PTO-152)				

Application/Control Number: 10/766,122 Page 2

Art Unit: 1624

DETAILED ACTION

1. Claims 1-30 are pending in this application.

Information Disclosure Statement

2. Applicant's Information Disclosure Statement, filed on 05/06/2004 has been acknowledged. Please refer to Applicant's copies of the 1449 submitted herewith.

Claim Objections

3. Claims 2-6, 9-11, 13 and 15 are objected because they duplicate claim 1. Claims 2-6 are drawn to the same crystal form recited in claim 1, but in more detailed way. For example, claim 4 recites the X-ray diffraction data from claim 1, the IR data from claim 2 and the melting point data from claim 3.

Likewise, the same problem appears with the pharmaceutical composition. The compositions in claims 9-11, 13 and 15 duplicate claim 7.

- 4. Claim 2 is objected to because the claim is missing the word "and" between the last two peaks i.e. 705, 684 cm⁻¹. It suggested that applicants amend claim 2 as "705 and 684 cm⁻¹."
- 5. Claims 28-30 are objected because the nomenclature of the crystalline product is defective or is inconsistent with the nomenclature used in the rest of the claims. The notation " $1\lambda^6$ " is missing between "1,1-dioxo" and "thiomorpholin".

Page 3

Application/Control Number: 10/766,122

Art Unit: 1624

Claim Rejections - 35 USC § 112

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claim 1 and claims dependent thereon are rejected because the phrase "crystalline modification" is not clear. Claim 1 appears to be a product claim, but the term "modification" implies a process. If applicants intend a compound claim, what does "modification" implies? How is modified crystalline compound different from unmodified crystalline compound? It is recommended that applicants use the phrase "crystalline form" or just "crystalline", if they intend a product claim.

7. At the time of rejoinder of the method claims 16-27, there would be an obviousness double patenting issues over co-pending application 10/196,795. In addition, there would be a 112 first paragraph issues.

Conclusion

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte, Ph. D. whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

Application/Control Number: 10/766,122 Page 4

Art Unit: 1624

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Wilson can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kahsay Habte, Ph. D Patent Examiner

Art Unit 1624

KH August 31, 2005